ClinicalTrials.gg
CompletedNCT01621178AWARD-7Updated Sep 19, 2019Results posted

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

A Phase 3 interventional study of Dulaglutide and Insulin glargine in Type 2 Diabetes and Chronic Kidney Disease, sponsored by Eli Lilly and Company. Completed at 89 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-19.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
577
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
15th of 54
577 · median 159
Started
2012
with 7 others
Phase 3
22 of 54
1 open now
Registered
23rd of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is one of 8 that started in 2012, is one of 22 in phase 3, and was the 23rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to determine the glycemic efficacy and safety of dulaglutide compared to insulin glargine in the treatment of participants with type 2 diabetes and moderate or severe chronic kidney disease.

03

Conditions studied

  • Type 2 Diabetes
  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and non-pregnant women aged ≥18 years
  • (HbA1c) ≥7.5% and ≤10.5%
  • Type 2 diabetes on insulin or insulin + oral antihyperglycemic medication
  • Participants with presumed diabetic kidney disease with or without hypertensive nephrosclerosis diagnosed with moderate or severe CKD with estimated (eGFR) of ≥15 to \<60 milliliters per minute (mL/min)/1.73 meter squared (m\^2)
  • Able and willing to perform multiple daily injections
  • (BMI) between 23 and 45 kilogram/square meter (kg/m\^2)

Exclusion criteria

Exclusion Criteria:

  • Stage 5 CKD as defined by \<15 mL/min/1.73 m\^2 OR having required dialysis
  • Rapidly progressing renal dysfunction likely to require renal replacement
  • History of a transplanted organ
  • Type 1 diabetes mellitus
  • At screening a systolic blood pressure of ≥150 mmHg or a diastolic blood pressure of ≥90 mmHg with or without antihypertensive medication
  • An episode of ketoacidosis or hyperosmolar state/coma in the past 6 months or a history of severe hypoglycemia in the past 3 months prior to the Screening Visit
  • Cardiovascular conditions within 12 weeks prior to randomization: acute myocardial infarction, (NYHA) class III or class IV heart failure, or cerebrovascular accident (stroke)
  • Acute or chronic hepatitis
  • Signs and symptoms of chronic or acute pancreatitis, or were in the past diagnosed with pancreatitis
  • Serum calcitonin ≥35 picograms per milliliter (pg/mL) at Screening Visit
  • Self or family history of medullary C-cell hyperplasia, focal hyperplasia, or carcinoma
  • Known history of untreated proliferative retinopathy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
577 participants (actual)

Study arms

  • Active comparator
    Insulin glargine

    Insulin glargine was administered subcutaneously (SC) at bedtime per a modified forced-titration treat-to-target algorithm. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.

    Drug: Insulin glargine · Drug: Insulin lispro

  • Experimental
    0.75 mg Dulaglutide

    0.75 milligram (mg) of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.

    Drug: Dulaglutide · Drug: Insulin lispro

  • Experimental
    1.5 mg Dulaglutide

    1.5 mg of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.

    Drug: Dulaglutide · Drug: Insulin lispro

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c)

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) means in HbA1c were calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, macroalbuminuria (MA) region, Baseline CKD Severity, week, treatment\*week, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.

    Time frame: Baseline, 26 Weeks

Secondary outcomes

  1. Percentage of Participants Whose HbA1c Was <7.0%

    Percentage of participants whose HbA1c was \<7.0% based on last observation carried forward (LOCF).

    Time frame: 26 Weeks

  2. Percentage of Participants Whose HbA1c Was <8.0%

    Percentage of Participants whose HbA1c was \<8.0% based on last observation carried forward (LOCF).

    Time frame: 26 Weeks

  3. Change From Baseline in 8-Point Self-Monitored Plasma Glucose (SMPG)

    The daily mean of 8-point SMPG profile at Week 26 is presented. Participants were required to perform two 8-point SMPG profiles over a 1-week period at 5 separate times throughout the study. LS means were calculated using the MMRM model including the corresponding baseline value as a continuous covariate, as well as baseline HbA1c, MA-region, treatment, week, treatment\*week, baseline CKD severity, and log baseline eGFR (within CKD severity).The two 8-point SMPG profiles were collected on two non-consecutive days (pre-meal and 2-hour postprandial SMPG x \[morning, midday, and evening meals in one day\] + bedtime + 5 hours after bedtime).

    Time frame: Baseline, 26 Weeks

  4. Change From Baseline in Fasting Glucose (FG)

    LS means were calculated using MMRM with the change in FG as the dependent variable and treatment, MA -region, Baseline CKD Severity, week, treatment\*week, baseline FG, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured

    Time frame: Baseline, 26 Weeks

  5. Change From Baseline in Mean Daily Insulin Lispro Dose

    The mean daily insulin was based on a 4-week interval prior to week 26 assessments. LS means were calculated using a REML based mixed-effects model for repeated measures (MMRM) with the change in mean daily insulin as the dependent variable and treatment, MA-region, Baseline HbA1c, baseline mean daily insulin, baseline CKD Severity, week, treatment\*week, log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.

    Time frame: Baseline, 26 Weeks

  6. Percentage of Participants With Estimated Average Glucose <154 mg/dL

    Percentage of Participants With Estimated Average Glucose \<154 milligram/deciliter (mg/dL) was based on last observation carried forward (LOCF).

    Time frame: 26 Weeks

  7. Change From Baseline in Serum Creatinine (sCr)

    Change from baseline in serum creatinine (sCr) levels after treatment.

    Time frame: Baseline, 26 Weeks

  8. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)

    The change in estimated glomerular filtration rate (eGFR) by using CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.

    Time frame: Baseline, 26 Weeks

  9. Change From Baseline in Estimated Creatinine Clearance (eCrCl)

    Estimated creatinine clearance (eCrCl) was calculated by Cockcroft-Gault \[Cockcroft and Gault 1976\] equation using baseline estimated lean body weight.

    Time frame: Baseline, 26 Weeks

  10. Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR)

    The change from baseline in Urinary Albumin to Creatinine Ratio (UACR).

    Time frame: Baseline, 26 Weeks

  11. Change From Baseline in Body Weight

    LS means were calculated from a REML based MMRM model: Change from Baseline = treatment, week, treatment\*Week, MA-region, Baseline HbA1c (%), Baseline Body Weight (kg), Baseline CKD Severity, Log Baseline eGFR (within CKD severity), where participant enters the model as a random effect. Covariance structure = Unstructured. •

    Time frame: Baseline, 26 Weeks

  12. Percentage of Participants With Self-Reported Hypoglycemic Events (HE)

    Hypoglycemic events (HE) were classified as severe (defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of ≤3.9 mmol/L (≤70 mg/dL), nocturnal (defined as any hypoglycemic event that occurs between bedtime and waking). The number of self-reported hypoglycemic events was summarized cumulatively at 26 weeks. A summary of other nonserious AEs, and all SAEs, regardless of causality, is located in the Reported Adverse Events section.

    Time frame: Baseline through 26 Weeks

  13. Rate of Hypoglycemic Events

    Hypoglycemic events (HE) were classified as total HE rate, documented symptomatic hypoglycemia, severe hypoglycemia, and nocturnal. The 1-year adjusted rate of HEs was summarized cumulatively at 26 weeks. A summary of other nonserious AEs, and all SAEs, regardless of causality, is located in the Reported Adverse Events section.

    Time frame: Baseline through 26 Weeks

  14. Change From Baseline in HbA1c

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS means in HbA1c were calculated using a REML based mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, MA region, Baseline CKD Severity, week, treatment\*week, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.

    Time frame: Baseline, 52 Weeks

  15. Percentage of Participants Whose HbA1c is <7.0%

    Percentage of participants whose HbA1c was \<7.0% based on last observation carried forward (LOCF).

    Time frame: 52 Weeks

  16. Percentage of Participants Whose HbA1c is <8.0%

    Percentage of participants whose HbA1c was \<8.0% based on last observation carried forward (LOCF).

    Time frame: 52 Weeks

  17. Change From Baseline in 8-Point SMPG

    The daily mean of 8-point SMPG profile at Week 52 is presented. Participants were required to perform two 8-point SMPG profiles over a 1-week period at 5 separate times throughout the study. LS means were calculated using the MMRM model including the corresponding baseline value as a continuous covariate, as well as baseline HbA1c, MA-region, treatment, week, treatment\*week, baseline CKD severity, and log baseline eGFR (within CKD severity).The two 8-point SMPG profiles were collected on two non-consecutive days (pre-meal and 2-hour postprandial SMPG x \[morning, midday, and evening meals in one day\] + bedtime + 5 hours after bedtime).

    Time frame: Baseline, 52 Weeks

  18. Change From Baseline in FG

    LS means were calculated using MMRM with the change in FG as the dependent variable and treatment, MA -region, Baseline CKD Severity, week, treatment\*week, baseline FG, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured

    Time frame: Baseline, 52 Weeks

  19. Change in Mean Daily Insulin Lispro Dose

    The mean daily insulin was based on a 4-week interval prior to week 52 assessments. LS means were calculated using a REML based mixed-effects model for repeated measures (MMRM) with the change in mean daily insulin as the dependent variable and treatment, MA-region, Baseline HbA1c, baseline mean daily insulin, baseline CKD Severity, week, treatment\*week, log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.

    Time frame: Baseline, 52 Weeks

  20. Percentage of Participants With Estimated Average Glucose <154 mg/dL

    Percentage of Participants With Estimated Average Glucose \<154 milligram/deciliter (mg/dL) was based on last observation carried forward (LOCF).

    Time frame: 52 Weeks

  21. Change From Baseline in sCr

    Change from baseline in sCr levels after treatment.

    Time frame: Baseline, 52 Weeks

  22. Change From Baseline in eGFR

    The change in eGFR by using CKD-EPI equation.

    Time frame: Baseline, 52 Weeks

  23. Change From Baseline in eCrCl

    eCrCl was calculated by Cockcroft-Gault \[Cockcroft and Gault 1976\] equation using baseline estimated lean body weight.

    Time frame: Baseline, 52 Weeks

  24. Change From Baseline in UACR

    The change from baseline in UACR

    Time frame: Baseline, 52 Weeks

  25. Change From Baseline in Body Weight

    LS means were calculated from a REML based MMRM model: Change from Baseline = treatment , week, treatment\*Week, MA-region, Baseline HbA1c (%), Baseline Body Weight (kg), Baseline CKD Severity, Log Baseline eGFR (within CKD severity), where participant enters the model as a random effect. Covariance structure = Unstructured.

    Time frame: Baseline, 52 Weeks

  26. Percentage of Participants With Self-Reported Hypoglycemic Events (HE)

    Hypoglycemic events (HE) were classified as severe (defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of ≤3.9 mmol/L (≤70 mg/dL), nocturnal (defined as any hypoglycemic event that occurs between bedtime and waking). The number of self-reported hypoglycemic events was summarized cumulatively at 52 weeks. A summary of other nonserious AEs, and all SAEs, regardless of causality, is located in the Reported Adverse Events section.

    Time frame: Baseline through 52 Weeks

  27. Rate of Hypoglycemic Events (HE)

    HE were classified as total HE rate, documented symptomatic hypoglycemia, severe hypoglycemia, and nocturnal. The 1-year adjusted rate of HEs was summarized cumulatively at 52 weeks. A summary of other nonserious AEs, and all SAEs, regardless of causality, is located in the Reported Adverse Events section.

    Time frame: Baseline through 52 Weeks

  28. Participants With Events of Allergic/Hypersensitivity Reactions

    Participants with Events of Allergic/Hypersensitivity Reactions: Angioedema Standardized MedDRA Query (SMQ), Anaphylactic Reaction SMQ, or Severe Cutaneous Adverse Reactions SMQ

    Time frame: Baseline through 52 Weeks

07

Results

Posted Jul 24, 2017

Participant flow

Participant flow — Overall Study
MilestoneInsulin Glargine0.75 mg Dulaglutide1.5 mg Dulaglutide
Started194190193
Received at least one dose of study drug194190192
Modified intent to treat population186180183
Completed163160157
Not completed313036
Withdrew: Adverse event528
Withdrew: Death672
Withdrew: Lost to follow-up121
Withdrew: Withdrawal by subject141718
Withdrew: Physician decision527

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c)

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) means in HbA1c were calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, macroalbuminuria (MA) region, Baseline CKD Severity, week, treatment\*week, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c)
percentage of HbA1cInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in Hemoglobin A1c (HbA1c)-1.13 ± 0.12-1.12 ± 0.12-1.19 ± 0.13
Statistical analysis
  • Insulin Glargine vs Dulaglutide 1.5 mg · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.05 · 95% CI -0.26 to 0.15
  • Insulin Glargine vs Dulaglutide 0.75 mg · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.02 · 95% CI -0.18 to 0.22
SecondaryPercentage of Participants Whose HbA1c Was <7.0%

Percentage of participants whose HbA1c was \<7.0% based on last observation carried forward (LOCF).

Time frame:
26 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Whose HbA1c Was <7.0%
percentage of participantsInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Percentage of Participants Whose HbA1c Was <7.0%34.631.737.5
SecondaryPercentage of Participants Whose HbA1c Was <8.0%

Percentage of Participants whose HbA1c was \<8.0% based on last observation carried forward (LOCF).

Time frame:
26 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Whose HbA1c Was <8.0%
percentage of participantsInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Percentage of Participants Whose HbA1c Was <8.0%75.372.678.3
SecondaryChange From Baseline in 8-Point Self-Monitored Plasma Glucose (SMPG)

The daily mean of 8-point SMPG profile at Week 26 is presented. Participants were required to perform two 8-point SMPG profiles over a 1-week period at 5 separate times throughout the study. LS means were calculated using the MMRM model including the corresponding baseline value as a continuous covariate, as well as baseline HbA1c, MA-region, treatment, week, treatment\*week, baseline CKD severity, and log baseline eGFR (within CKD severity).The two 8-point SMPG profiles were collected on two non-consecutive days (pre-meal and 2-hour postprandial SMPG x \[morning, midday, and evening meals in one day\] + bedtime + 5 hours after bedtime).

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · milligrams/deciliter (mg/dL)
Change From Baseline in 8-Point Self-Monitored Plasma Glucose (SMPG)
milligrams/deciliter (mg/dL)Insulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in 8-Point Self-Monitored Plasma Glucose (SMPG)-37.6 ± 3.41-31.7 ± 3.53-33.7 ± 3.77
SecondaryChange From Baseline in Fasting Glucose (FG)

LS means were calculated using MMRM with the change in FG as the dependent variable and treatment, MA -region, Baseline CKD Severity, week, treatment\*week, baseline FG, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · milligram/deciliter (mg/dL)
Change From Baseline in Fasting Glucose (FG)
milligram/deciliter (mg/dL)Insulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in Fasting Glucose (FG)-19.1 ± 6.0017.7 ± 6.1423.1 ± 6.50
SecondaryChange From Baseline in Mean Daily Insulin Lispro Dose

The mean daily insulin was based on a 4-week interval prior to week 26 assessments. LS means were calculated using a REML based mixed-effects model for repeated measures (MMRM) with the change in mean daily insulin as the dependent variable and treatment, MA-region, Baseline HbA1c, baseline mean daily insulin, baseline CKD Severity, week, treatment\*week, log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · Units/day (U/day)
Change From Baseline in Mean Daily Insulin Lispro Dose
Units/day (U/day)Insulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in Mean Daily Insulin Lispro Dose16.64 ± 2.7626.16 ± 2.8018.12 ± 3.00
SecondaryPercentage of Participants With Estimated Average Glucose <154 mg/dL

Percentage of Participants With Estimated Average Glucose \<154 milligram/deciliter (mg/dL) was based on last observation carried forward (LOCF).

Time frame:
26 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Estimated Average Glucose <154 mg/dL
percentage of participantsInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Percentage of Participants With Estimated Average Glucose <154 mg/dL64.952.556.4
SecondaryChange From Baseline in Serum Creatinine (sCr)

Change from baseline in serum creatinine (sCr) levels after treatment.

Time frame:
Baseline, 26 Weeks
Reported as:
Median · mg/dL
Change From Baseline in Serum Creatinine (sCr)
mg/dLInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in Serum Creatinine (sCr)0.10 (-0.04 to 0.28)0.02 (-0.15 to 0.15)0.04 (-0.14 to 0.20)
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate (eGFR)

The change in estimated glomerular filtration rate (eGFR) by using CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.

Time frame:
Baseline, 26 Weeks
Reported as:
Median · milliliter/minute/1.73m2 (mL/min/1.73m2)
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)
milliliter/minute/1.73m2 (mL/min/1.73m2)Insulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)-2.5 (-6.0 to 1.0)-1.0 (-4.5 to 3.0)-1.0 (-5.5 to 3.0)
SecondaryChange From Baseline in Estimated Creatinine Clearance (eCrCl)

Estimated creatinine clearance (eCrCl) was calculated by Cockcroft-Gault \[Cockcroft and Gault 1976\] equation using baseline estimated lean body weight.

Time frame:
Baseline, 26 Weeks
Reported as:
Median · milliliter/minute (ml/min)
Change From Baseline in Estimated Creatinine Clearance (eCrCl)
milliliter/minute (ml/min)Insulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in Estimated Creatinine Clearance (eCrCl)-2.0 (-4.0 to 0.5)-1.0 (-3.5 to 2.0)-0.5 (-4.0 to 2.0)
SecondaryChange From Baseline in Urinary Albumin to Creatinine Ratio (UACR)

The change from baseline in Urinary Albumin to Creatinine Ratio (UACR).

Time frame:
Baseline, 26 Weeks
Reported as:
Median · gram/kilogram (g/kg)
Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR)
gram/kilogram (g/kg)Insulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR)-1.3 (-71.7 to 62.0)-11.1 (-147.8 to 33.2)-10.2 (-180.5 to 53.1)
SecondaryChange From Baseline in Body Weight

LS means were calculated from a REML based MMRM model: Change from Baseline = treatment, week, treatment\*Week, MA-region, Baseline HbA1c (%), Baseline Body Weight (kg), Baseline CKD Severity, Log Baseline eGFR (within CKD severity), where participant enters the model as a random effect. Covariance structure = Unstructured. •

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight
kilogram (kg)Insulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in Body Weight1.11 ± 0.346-2.02 ± 0.357-2.81 ± 0.374
SecondaryPercentage of Participants With Self-Reported Hypoglycemic Events (HE)

Hypoglycemic events (HE) were classified as severe (defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of ≤3.9 mmol/L (≤70 mg/dL), nocturnal (defined as any hypoglycemic event that occurs between bedtime and waking). The number of self-reported hypoglycemic events was summarized cumulatively at 26 weeks. A summary of other nonserious AEs, and all SAEs, regardless of causality, is located in the Reported Adverse Events section.

Time frame:
Baseline through 26 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Self-Reported Hypoglycemic Events (HE)
percentage of participantsInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Total Hypo71.650.843.2
Documented Symptomatic Hypo60.340.731.6
Severe Hypo4.11.10
Nocturnal Hypo38.115.913.2
SecondaryRate of Hypoglycemic Events

Hypoglycemic events (HE) were classified as total HE rate, documented symptomatic hypoglycemia, severe hypoglycemia, and nocturnal. The 1-year adjusted rate of HEs was summarized cumulatively at 26 weeks. A summary of other nonserious AEs, and all SAEs, regardless of causality, is located in the Reported Adverse Events section.

Time frame:
Baseline through 26 Weeks
Reported as:
Mean · Events/Participant/Year
Rate of Hypoglycemic Events
Events/Participant/YearInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Total HE Rate17.07 ± 27.707.76 ± 20.395.45 ± 12.54
Documented Symptomatic HE Rate11.34 ± 22.044.86 ± 13.374.19 ± 11.58
Severe HE Rate0.10 ± 0.560.03 ± 0.310.00 ± 0.00
Nocturnal HE Rate3.06 ± 7.260.73 ± 2.250.63 ± 2.26
SecondaryChange From Baseline in HbA1c

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS means in HbA1c were calculated using a REML based mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, MA region, Baseline CKD Severity, week, treatment\*week, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.

Time frame:
Baseline, 52 Weeks
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in HbA1c
percentage of HbA1cInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in HbA1c-1.00 ± 0.12-1.10 ± 0.12-1.10 ± 0.13
SecondaryPercentage of Participants Whose HbA1c is <7.0%

Percentage of participants whose HbA1c was \<7.0% based on last observation carried forward (LOCF).

Time frame:
52 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Whose HbA1c is <7.0%
percentage of participantsInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Percentage of Participants Whose HbA1c is <7.0%29.133.532.9
SecondaryPercentage of Participants Whose HbA1c is <8.0%

Percentage of participants whose HbA1c was \<8.0% based on last observation carried forward (LOCF).

Time frame:
52 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Whose HbA1c is <8.0%
percentage of participantsInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Percentage of Participants Whose HbA1c is <8.0%70.369.569.1
SecondaryChange From Baseline in 8-Point SMPG

The daily mean of 8-point SMPG profile at Week 52 is presented. Participants were required to perform two 8-point SMPG profiles over a 1-week period at 5 separate times throughout the study. LS means were calculated using the MMRM model including the corresponding baseline value as a continuous covariate, as well as baseline HbA1c, MA-region, treatment, week, treatment\*week, baseline CKD severity, and log baseline eGFR (within CKD severity).The two 8-point SMPG profiles were collected on two non-consecutive days (pre-meal and 2-hour postprandial SMPG x \[morning, midday, and evening meals in one day\] + bedtime + 5 hours after bedtime).

Time frame:
Baseline, 52 Weeks
Reported as:
Least squares mean · mg/dL
Change From Baseline in 8-Point SMPG
mg/dLInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in 8-Point SMPG-40.5 ± 3.59-30.0 ± 3.75-27.2 ± 3.93
SecondaryChange From Baseline in FG

LS means were calculated using MMRM with the change in FG as the dependent variable and treatment, MA -region, Baseline CKD Severity, week, treatment\*week, baseline FG, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured

Time frame:
Baseline, 52 Weeks
Reported as:
Least squares mean · mg/dL
Change From Baseline in FG
mg/dLInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in FG-6.4 ± 6.3820.8 ± 6.5828.3 ± 6.87
SecondaryChange in Mean Daily Insulin Lispro Dose

The mean daily insulin was based on a 4-week interval prior to week 52 assessments. LS means were calculated using a REML based mixed-effects model for repeated measures (MMRM) with the change in mean daily insulin as the dependent variable and treatment, MA-region, Baseline HbA1c, baseline mean daily insulin, baseline CKD Severity, week, treatment\*week, log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.

Time frame:
Baseline, 52 Weeks
Reported as:
Least squares mean · U/day
Change in Mean Daily Insulin Lispro Dose
U/dayInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change in Mean Daily Insulin Lispro Dose16.84 ± 2.8727.46 ± 2.9320.05 ± 3.13
SecondaryPercentage of Participants With Estimated Average Glucose <154 mg/dL

Percentage of Participants With Estimated Average Glucose \<154 milligram/deciliter (mg/dL) was based on last observation carried forward (LOCF).

Time frame:
52 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Estimated Average Glucose <154 mg/dL
percentage of participantsInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Percentage of Participants With Estimated Average Glucose <154 mg/dL73.757.450.9
SecondaryChange From Baseline in sCr

Change from baseline in sCr levels after treatment.

Time frame:
Baseline, 52 Weeks
Reported as:
Median · mg/dL
Change From Baseline in sCr
mg/dLInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in sCr0.12 (-0.05 to 0.38)0.04 (-0.11 to 0.27)0.07 (-0.11 to 0.21)
SecondaryChange From Baseline in eGFR

The change in eGFR by using CKD-EPI equation.

Time frame:
Baseline, 52 Weeks
Reported as:
Median · mL/min/1.73m2
Change From Baseline in eGFR
mL/min/1.73m2Insulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in eGFR-3.3 (-7.5 to 1.0)-1.5 (-5.5 to 2.5)-2.0 (-6.0 to 2.5)
SecondaryChange From Baseline in eCrCl

eCrCl was calculated by Cockcroft-Gault \[Cockcroft and Gault 1976\] equation using baseline estimated lean body weight.

Time frame:
Baseline, 52 Weeks
Reported as:
Median · mL/min
Change From Baseline in eCrCl
mL/minInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in eCrCl-2.5 (-5.8 to 0.5)-1.3 (-4.0 to 1.5)-1.5 (-5.0 to 1.5)
SecondaryChange From Baseline in UACR

The change from baseline in UACR

Time frame:
Baseline, 52 Weeks
Reported as:
Median · g/kg
Change From Baseline in UACR
g/kgInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in UACR3.5 (-56.2 to 138.1)-3.0 (-88.5 to 87.6)-11.5 (-158.0 to 42.9)
SecondaryChange From Baseline in Body Weight

LS means were calculated from a REML based MMRM model: Change from Baseline = treatment , week, treatment\*Week, MA-region, Baseline HbA1c (%), Baseline Body Weight (kg), Baseline CKD Severity, Log Baseline eGFR (within CKD severity), where participant enters the model as a random effect. Covariance structure = Unstructured.

Time frame:
Baseline, 52 Weeks
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight
kgInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Change From Baseline in Body Weight1.57 ± 0.429-1.71 ± 0.448-2.66 ± 0.467
SecondaryPercentage of Participants With Self-Reported Hypoglycemic Events (HE)

Hypoglycemic events (HE) were classified as severe (defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of ≤3.9 mmol/L (≤70 mg/dL), nocturnal (defined as any hypoglycemic event that occurs between bedtime and waking). The number of self-reported hypoglycemic events was summarized cumulatively at 52 weeks. A summary of other nonserious AEs, and all SAEs, regardless of causality, is located in the Reported Adverse Events section.

Time frame:
Baseline through 52 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Self-Reported Hypoglycemic Events (HE)
percentage of participantsInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Total Hypo74.759.850.0
Documented Symptomatic Hypo63.448.140.5
Severe Hypo6.72.60
Nocturnal Hypo47.923.820.5
SecondaryRate of Hypoglycemic Events (HE)

HE were classified as total HE rate, documented symptomatic hypoglycemia, severe hypoglycemia, and nocturnal. The 1-year adjusted rate of HEs was summarized cumulatively at 52 weeks. A summary of other nonserious AEs, and all SAEs, regardless of causality, is located in the Reported Adverse Events section.

Time frame:
Baseline through 52 Weeks
Reported as:
Mean · Events/Participant/Year
Rate of Hypoglycemic Events (HE)
Events/Participant/YearInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Total HE Rate14.36 ± 22.207.59 ± 17.815.82 ± 13.70
Documented Symptomatic HE Rate9.62 ± 17.724.34 ± 9.304.44 ± 12.23
Severe HE Rate0.09 ± 0.370.03 ± 0.210.00 ± 0.00
Nocturnal HE Rate2.48 ± 5.100.76 ± 2.090.70 ± 2.29
SecondaryParticipants With Events of Allergic/Hypersensitivity Reactions

Participants with Events of Allergic/Hypersensitivity Reactions: Angioedema Standardized MedDRA Query (SMQ), Anaphylactic Reaction SMQ, or Severe Cutaneous Adverse Reactions SMQ

Time frame:
Baseline through 52 Weeks
Reported as:
Number · participants with events
Participants With Events of Allergic/Hypersensitivity Reactions
participants with eventsInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Angioedema SMQ122
Angioedema001
Eyelid edema010
Face edema011
Urticaria100
Anaphylactic Reaction SMQ100
Circulatory collapse100
Severe Cutaneous Adverse Reactions SMQ000

Adverse events

Collected over Up To Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Glargine—56/194 (28.9%)130/194 (67%)
Dulaglutide 0.75 mg—48/190 (25.3%)134/190 (70.5%)
Dulaglutide 1.5 mg—41/192 (21.4%)144/192 (75%)
Most frequent serious events
Showing 10 of 122
Most frequent serious events
EventInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
HypoglycaemiaMetabolism and nutrition disorders13/1946/1901/192
Acute myocardial infarctionCardiac disorders4/1946/1900/192
Acute kidney injuryRenal and urinary disorders2/1945/1903/192
PneumoniaInfections and infestations3/1943/1900/192
Blood creatinine increasedInvestigations2/1943/1903/192
Cardiac failureCardiac disorders1/1941/1903/192
Chest painGeneral disorders0/1940/1903/192
Angina unstableCardiac disorders3/1942/1901/192
CellulitisInfections and infestations3/1940/1901/192
Urinary tract infectionInfections and infestations3/1942/1901/192
Most frequent other events
Showing 10 of 20
Most frequent other events
EventInsulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mg
Blood creatinine increasedInvestigations90/19471/19074/192
NauseaGastrointestinal disorders9/19427/19038/192
DiarrhoeaGastrointestinal disorders14/19430/19031/192
VomitingGastrointestinal disorders9/19416/19026/192
Glomerular filtration rate decreasedInvestigations26/19420/19017/192
Upper respiratory tract infectionInfections and infestations20/19413/1908/192
HypertensionVascular disorders20/19413/19014/192
Urinary tract infectionInfections and infestations19/19410/19013/192
Weight increasedInvestigations16/1949/1909/192
InfluenzaInfections and infestations10/19415/19012/192

Baseline characteristics

All participants who received at least one dose of study drug and had evaluable post-baseline measurements.

Age, Continuous
Age, Continuous(years)Insulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mgTotal
Mean64.3 ± 8.4164.7 ± 8.6164.7 ± 8.8364.6 ± 8.60
Sex: Female, Male
Sex: Female, Male(Participants)Insulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mgTotal
Female1018688275
Male93104104301
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mgTotal
Hispanic or Latino797578232
Not Hispanic or Latino115115114344
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mgTotal
American Indian or Alaska Native18171247
Asian54716
Native Hawaiian or Other Pacific Islander1001
Black or African American26362688
White137122134393
More than one race671023
Unknown or Not Reported1438
Region of Enrollment
Region of Enrollment(Participants)Insulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mgTotal
Romania1491437
Hungary22191455
United States615962182
Ukraine17111240
Brazil444750141
Poland1225
Mexico19191553
South Africa14201751
Spain24612
Body Weight
Body Weight(kilogram (kg))Insulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mgTotal
Mean88.20 ± 18.48890.88 ± 18.30188.14 ± 16.01589.06 ± 17.653
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram/square meter (kg/m^2))Insulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mgTotal
Mean32.39 ± 5.32433.00 ± 5.54632.11 ± 4.84132.50 ± 5.248
Hemoglobin A1C (HbA1c) at Baseline
Hemoglobin A1C (HbA1c) at Baseline(Percentage of HbA1c)Insulin GlargineDulaglutide 0.75 mgDulaglutide 1.5 mgTotal
Mean8.56 ± 0.9668.57 ± 1.0888.59 ± 0.8608.57 ± 0.973

3 further baseline measures are reported on the registry.

08

Study locations

89 sites
  • Extended Arm Physician, Inc.
    Montgomery, Alabama 36106, United States
  • North American Research Institute
    Azusa, California 91702, United States
  • Renal Consultants Medical Group
    Granada Hills, California 91344, United States
  • Marin Endocrine Associates
    Greenbrae, California 94904, United States
  • Academic Medical Research Institute
    Los Angeles, California 90022, United States
  • Sutter Gould Medical Foundation
    Modesto, California 95355, United States
  • Infosphere
    West Hills, California 91307, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • The Center for Diabetes & Endocrine Care
    Hollywood, Florida 33312, United States
  • East Coast Clinical Research
    Jacksonville, Florida 32204, United States
  • Ocean Blue Medical Research Center, Inc.
    Miami Springs, Florida 33166, United States
  • San Marcus Research Clinic, Inc.
    Miami, Florida 33015, United States
  • Pharmax Research Clinic
    Miami, Florida 33126, United States
  • Avanced Medical and Pain Mangement Research Clinic (AMPM)
    Miami, Florida 33145, United States
  • Baptist Diabetes Association
    Miami, Florida 33156, United States
  • Suncoast Clinical Research
    New Port Richey, Florida 34652, United States
  • Discovery Medical Research Group
    Ocala, Florida 34471, United States
  • Suncoast Clinical Research
    Palm Harbor, Florida 34684, United States
  • University of Hawaii Clinical Research
    Honolulu, Hawaii 96813, United States
  • Boise Kidney & Hypertension Institute
    Caldwell, Idaho 83605, United States
  • Pacific Renal Research Institute
    Meridian, Idaho 83642, United States
  • Cotton O'Neil Clinic
    Topeka, Kansas 66606, United States
  • Univ of Kansas Schl of Medicine , Wichita
    Wichita, Kansas 67214, United States
  • Penobscot Bay Medical Center
    Rockport, Maine 04854, United States
  • Nebraska Nephrology Research Institute, LLC
    Lincoln, Nebraska 68510, United States
  • Endocrine Group, LLP
    Albany, New York 12206, United States
  • Erie County Medical Center State University
    Buffalo, New York 14215, United States
  • Institute for clinical studies
    Rosedale, New York 11422, United States
  • Endocrine Associates of Long Island, PC
    Smithtown, New York 11787, United States
  • Carolina Clinical Trials LLC
    Concord, North Carolina 28025, United States
  • Physicians East
    Greenville, North Carolina 27834, United States
  • Diabetes & Endocrinology Consultants PC
    Morehead City, North Carolina 28557, United States
  • Boice Willis Clinic, PA
    Rocky Mount, North Carolina 27804, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Partners in Nephrology & Endocrinology
    Pittsburgh, Pennsylvania 15224, United States
  • South Carolina Nephrology and Hypertension Center, Inc.
    Orangeburg, South Carolina 29118, United States
  • Carolina Diabetes & Kidney Ctr. Sumter Medical Specialist
    Sumter, South Carolina 29150, United States
  • Southeast Renal Research Institute
    Chattanooga, Tennessee 37408, United States
  • Knoxville Kidney Center, PLLC
    Knoxville, Tennessee 37923, United States
  • Center For Clinical Research
    Austin, Texas 78758, United States
  • Endocrine Associates of Dallas
    Dallas, Texas 75231, United States
  • Office of Dr. Sergio Rovner
    El Paso, Texas 79925, United States
  • Endocrine Associates, LLC
    Houston, Texas 77004, United States
  • Juno Research
    Houston, Texas 77036, United States
  • The Endocrine Center
    Houston, Texas 77079, United States
  • San Antonio Kidney Disease Center Physicians Group
    San Antonio, Texas 78229, United States
  • Providence Health & Services
    Spokane, Washington 99204, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Belem, 66073-000, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Curitiba, 80240-000, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Juiz De Fora, 36036-330, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Passo Fundo, 99010-080, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Porto Alegre, 90610000, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santa Catarina, 89227680, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    São Paulo, 04025-011, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Baja, 6500, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Budapest, 1036, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Esztergom, 2500, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kaposvar, 7400, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kecskemet, 6000, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pecs, 7623, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Satoraljaujhely, H-3980, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Siofok, 8600, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chihuahua, 31000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Culiacan, 80030, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guadalajara, 44650, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 11850, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gdansk, 80-952, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lodz, 90302, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szczecin, 70-111, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zgierz, 95-100, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bacau, 600114, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucharest, 020045, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Deva, 330084, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oradea, 410167, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Targu Mures, 540142, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Timisoara, 300125, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cape Town, 7925, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Durban, 4091, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Johannesburg, 2198, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Somerset West, 7130, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Worcester, 6850, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08036, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Valencia, 46026, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dnipropetrovsk, 49005, Ukraine
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kyiv, 2091, Ukraine
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lugansk, 91045, Ukraine
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poltava, 36011, Ukraine
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ternopil, 46002, Ukraine
09

References and documents

Publications

  • Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018 Aug;6(8):605-617. doi: 10.1016/S2213-8587(18)30104-9. Epub 2018 Jun 14. PubMed 29910024 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Jun 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2012
First posted
Jun 18, 2012
Start
Jul 2012
Primary completionActual
Jun 2016
CompletionActual
Dec 2016
Results first posted
Jul 24, 2017
Last update
Sep 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01621178
Responsible party
Sponsor
First posted
Jun 18, 2012
Start date
Jul 2012
Primary completion
Jun 2016
Completion
Dec 2016
Results posted
Jul 24, 2017
Last update
Sep 19, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion